📊 VRTX Key Takeaways
Is Vertex Pharmaceuticals Inc. / Ma (VRTX) a Good Investment?
Vertex demonstrates exceptional financial fundamentals with a fortress balance sheet (0.01x D/E), exceptional profitability (34.5% net margin), and robust cash generation ($1.3B FCF). However, modest 8.9% revenue growth and unusual 838% YoY earnings spike warrant scrutiny on sustainability and capital efficiency.
Vertex Pharmaceuticals shows high-quality fundamentals with strong operating profitability, excellent free cash flow generation, and an exceptionally conservative balance sheet. Revenue growth remains solid, while margins and returns on capital are strong, but the extreme year-over-year jump in net income suggests some earnings volatility or prior-period distortion that should be monitored for sustainability.
Why Buy Vertex Pharmaceuticals Inc. / Ma Stock? VRTX Key Strengths
- Exceptional profitability: 34.5% net margin and 38.1% operating margin demonstrate operational excellence and pricing power
- Fortress balance sheet: Minimal debt (0.01x D/E), $5.5B cash, and 3.02x current ratio provide strategic flexibility and financial security
- High-quality earnings: $1.3B free cash flow with 43.3% FCF margin shows earnings are backed by real cash generation, not accounting artifacts
- High profitability with 34.8% operating margin and 32.9% net margin
- Very strong financial health with 2.90x current ratio, 0.01x debt/equity, and $5.08B in cash
- Robust cash generation with $3.19B in free cash flow and 26.6% FCF margin
VRTX Stock Risks: Vertex Pharmaceuticals Inc. / Ma Investment Risks
- Unsustainable earnings spike: 838% YoY net income growth likely reflects prior year loss/restructuring; normalized earnings power unclear
- Capital inefficiency: Low ROE (5.3%) and ROA (3.9%) despite exceptional net margin suggest excess capital or trapped value in intangible assets
- Growth deceleration: Modest 8.9% revenue growth may indicate pipeline maturity, market saturation, or competitive pressures in core franchises
- Net income growth far exceeded revenue growth, which may indicate non-recurring items or difficult comparability
- Revenue growth of 8.9% is healthy but not exceptional for a pharmaceutical company facing pipeline and product-cycle risk
- Gross margin data is unavailable, limiting visibility into cost structure resilience
Key Metrics to Watch
- Normalized net income trajectory post-recovery to assess sustainable earnings power
- Revenue growth acceleration and product pipeline advancement (critical for pharma valuation)
- Return on equity improvement and capital allocation decisions (share buybacks, R&D investment, M&A)
- Sustainability of operating margin and net income versus more modest revenue growth
- Free cash flow conversion and revenue growth trajectory in upcoming filings
Vertex Pharmaceuticals Inc. / Ma (VRTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 43.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.02x current ratio provides a solid financial cushion.
VRTX Profit Margin, ROE & Profitability Analysis
VRTX vs Healthcare Sector: How Vertex Pharmaceuticals Inc. / Ma Compares
How Vertex Pharmaceuticals Inc. / Ma compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vertex Pharmaceuticals Inc. / Ma Stock Overvalued? VRTX Valuation Analysis 2026
Based on fundamental analysis, Vertex Pharmaceuticals Inc. / Ma has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vertex Pharmaceuticals Inc. / Ma Balance Sheet: VRTX Debt, Cash & Liquidity
VRTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vertex Pharmaceuticals Inc. / Ma's revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $13.89 reflects profitable operations.
VRTX Revenue Growth, EPS Growth & YoY Performance
VRTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8B | $646.3M | $2.49 |
| Q3 2025 | $2.8B | $1.0B | $4.01 |
| Q2 2025 | $2.6B | $1.0B | $3.99 |
| Q1 2025 | $2.7B | $646.3M | $2.49 |
| Q3 2024 | $2.5B | $1.0B | $3.97 |
| Q2 2024 | $2.5B | $915.7M | $3.52 |
| Q1 2024 | $2.4B | $699.8M | $2.69 |
| Q3 2023 | $2.3B | $930.5M | $3.59 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vertex Pharmaceuticals Inc. / Ma Dividends, Buybacks & Capital Allocation
VRTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vertex Pharmaceuticals Inc. / Ma (CIK: 0000875320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VRTX
What is the AI rating for VRTX?
Vertex Pharmaceuticals Inc. / Ma (VRTX) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are VRTX's key strengths?
Claude: Exceptional profitability: 34.5% net margin and 38.1% operating margin demonstrate operational excellence and pricing power. Fortress balance sheet: Minimal debt (0.01x D/E), $5.5B cash, and 3.02x current ratio provide strategic flexibility and financial security. ChatGPT: High profitability with 34.8% operating margin and 32.9% net margin. Very strong financial health with 2.90x current ratio, 0.01x debt/equity, and $5.08B in cash.
What are the risks of investing in VRTX?
Claude: Unsustainable earnings spike: 838% YoY net income growth likely reflects prior year loss/restructuring; normalized earnings power unclear. Capital inefficiency: Low ROE (5.3%) and ROA (3.9%) despite exceptional net margin suggest excess capital or trapped value in intangible assets. ChatGPT: Net income growth far exceeded revenue growth, which may indicate non-recurring items or difficult comparability. Revenue growth of 8.9% is healthy but not exceptional for a pharmaceutical company facing pipeline and product-cycle risk.
What is VRTX's revenue and growth?
Vertex Pharmaceuticals Inc. / Ma reported revenue of $3.0B.
Does VRTX pay dividends?
Vertex Pharmaceuticals Inc. / Ma does not currently pay dividends.
Where can I find VRTX SEC filings?
Official SEC filings for Vertex Pharmaceuticals Inc. / Ma (CIK: 0000875320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VRTX's EPS?
Vertex Pharmaceuticals Inc. / Ma has a diluted EPS of $4.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VRTX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Vertex Pharmaceuticals Inc. / Ma has a BUY rating with 81% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is VRTX stock overvalued or undervalued?
Valuation metrics for VRTX: ROE of 5.3% (sector avg: 15%), net margin of 34.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VRTX stock in 2026?
Our dual AI analysis gives Vertex Pharmaceuticals Inc. / Ma a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VRTX's free cash flow?
Vertex Pharmaceuticals Inc. / Ma's operating cash flow is $1.4B, with capital expenditures of $133.4M. FCF margin is 43.3%.
How does VRTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 34.5% (avg: 12%), ROE 5.3% (avg: 15%), current ratio 3.02 (avg: 2).